Aristopharma Ltd

News

 

Aristopharma has launched Livcare 5 & 10 mg Tablet for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) including Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC)

Livcare (Obeticholic Acid) is a selective Farnesoid X Receptor (FXR) agonist with anticholestatic & hepato-protective properties. Due to these promising effects, Livcare (Obeticholic Acid) is a novel treatment option for Non-Alcoholic Fatty Liver Disease (NAFLD) including Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC). Its multiple mechanism, metabolic effects & convenient once daily dose ensure clear superiority over Ursodeoxycholic Acid (UDCA). Obeticholic acid (Livcare) is also recommended and approved by USFDA, European Medicine Agency and American College of Gastroenterology society.